MDMA

MDMA

Empathogen-entactogen used in therapeutic settings for PTSD

🚀 Start Tracking

What is it?

MDMA (3,4-Methylenedioxymethamphetamine) is a substituted amphetamine and phenethylamine derivative classified as an **entactogen-empathogen**. Unlike classical psychedelics (LSD, psilocybin) which act as serotonin receptor agonists, MDMA is a serotonin-norepinephrine-dopamine releasing agent (SNDRA) that forces massive release of these neurotransmitters from nerve terminals.

First synthesized in 1912 by Merck pharmaceutical company, it was rediscovered in the 1970s by chemist Alexander Shulgin, who introduced it to the therapeutic community. MAPS has conducted extensive Phase 2 and Phase 3 clinical trials investigating MDMA-assisted therapy for PTSD, with approximately 67-71% of participants no longer meeting PTSD diagnostic criteria after treatment.

**⚠️ Why Controversial for Microdosing:**
- Depletes serotonin rather than mimicking it
- Has documented neurotoxicity with repeated use
- Cannot be used frequently without harm
- Has NO scientific support for microdosing
- Causes cardiovascular strain even at low doses

**Testing essential** - 87% of seized "molly" (2009-2013) contained ZERO MDMA.

🚨 Important Warnings

Please read all warnings carefully before use.

⚠️
HIGH

TEST YOUR SUBSTANCE. 87% of "molly" seized 2009-2013 contained ZERO MDMA. Street MDMA often contains dangerous adulterants (PMA, PMMA, bath salts, fentanyl). Use reagent test kits (Marquis: purple-black = MDMA). Lab testing (DrugsData) is more accurate.

⚠️
HIGH

Serotonin neuron damage with repeated use. Dose-dependent destruction of 5-HT axon terminals. Recovery requires 6-12+ months of abstinence. Some primates showed incomplete recovery after 7 YEARS. "Losing the magic" = permanent tolerance indicates serotonergic system damage.

⚠️
HIGH

MINIMUM 3-6 MONTHS BETWEEN USES ("Three Month Rule"). Unlike psilocybin/LSD which can be used weekly, MDMA depletes serotonin stores with each use. The brain needs months to fully replenish serotonin and repair potential neuronal damage. More frequent use leads to tolerance, diminished effects, prolonged depression, and increased neurotoxicity risk.

⚠️
CRITICAL

⚠️ MDMA microdosing is NOT scientifically validated and carries SIGNIFICANTLY HIGHER RISKS than psilocybin or LSD microdosing. No clinical trials exist. Reddit r/microdosing community explicitly warns: "DO NOT MICRODOSE MDMA." MDMA cannot be used frequently without harm.

⚠️ Interactions & Combinations

Important information about drug interactions and combinations. Always consult a physician before combining.

MAOIs

SEVERE

LIFE-THREATENING

MAOIs prevent serotonin breakdown; MDMA causes massive release → catastrophic serotonin syndrome, hyperthermia, multi-organ failure. ABSOLUTE CONTRAINDICATION. Wait 2+ weeks after stopping irreversible MAOIs. Multiple documented fatalities.

Lithium

SEVERE

HIGH SEIZURE RISK

47% of lithium + psychedelic reports involved seizures (Nayak et al. 2021). Mechanism not fully understood; possible serotonin potentiation and electrolyte effects. CONTRAINDICATED.

Stimulants

SEVERE

Dangerous combination

Additive cardiovascular strain, hyperthermia, serotonin syndrome risk. Risk of cardiac events, dangerous hyperthermia, psychosis. AVOID.

SSRIs

HIGH

Reduced efficacy + risk

SSRIs BLOCK MDMA effects by occupying SERT. Users may dangerously increase dose to "break through". MDMA will not work on SSRIs. Do NOT increase dose. Wait 2+ weeks after stopping (5 weeks for fluoxetine).

Tricyclic Antidepressants

HIGH

Cardiac risk

TCAs prolong QT interval; combined with MDMA cardiac effects increases arrhythmia risk. AVOID.

Antipsychotics

HIGH

Variable - drug specific

Olanzapine: INCREASED MORTALITY RISK - AVOID. Haloperidol: Increased anxiety/dysphoria with MDMA. Risperidone: May attenuate MDMA effects. Based on FAERS analysis (Cohen et al. 2021).

Alcohol

HIGH

Dehydration + masking

65-75% of MDMA users combine with alcohol. Both increase dehydration, hyperthermia risk; MDMA masks alcohol intoxication. Alcohol implicated in 75% of MDMA-related ER visits. Minimize or avoid.

💊 Dosage Guidelines

Typical dosage ranges from sub-perceptual microdoses to full psychoactive doses

🔬

Microdose

10.0 mg

Sub-perceptual

Always start with the lowest dose and gradually increase. Individual sensitivity varies greatly. Never exceed recommended doses without proper research and preparation.

🧪 Preparation

Preparation methods and handling tips for accurate dosing.

Volumetric

Steps:

  • Weigh MDMA precisely using milligram scale
  • Dissolve known quantity in measured volume of distilled water (e.g., 100mg in 100ml = 1mg/ml)
  • Store in amber glass bottle in cool, dark place
  • Shake thoroughly before each use (MDMA can precipitate)
  • Measure desired dose using oral syringe
Shelf life: Weeks to months in proper storage; check for mold/contamination before use

Capsule

Shelf life: Years if stored properly (cool, dark, dry, airtight)

✨ Reported Effects

🤝

Empathy & Social Connection

Increased feelings of closeness and empathy; reduced social anxiety reported even at sub-perceptual doses

😊

Mood Enhancement

Improved emotional well-being through serotonin, dopamine and norepinephrine release

😌

Emotional Openness

Greater ease in processing difficult emotions and increased emotional receptivity

Mild Energy Boost

Subtle increase in alertness and motivation at microdose levels without stimulant-like side effects

🎯

Improved Focus

Enhanced task engagement and concentration reported at very low doses in some individuals

⚠️ Safety Information

Use only in emotionally safe, controlled settings. Do not re-dose within 3 months to reduce neurotoxicity risk. Never combine with SSRIs, MAOIs, lithium, or other serotonergic substances — risk of serotonin syndrome. Stay hydrated but avoid overdrinking water. Always test substances with a reagent kit before use. Avoid if you have cardiovascular conditions, psychosis history, or are pregnant.

🔬 Scientific Research

Current research findings and clinical studies.

67% no longer met PTSD criteria after MDMA-assisted therapy. Phase 3 trials completed 2021.

Institution: MAPS

67% of MDMA group no longer met PTSD criteria vs. 32% placebo. Effect size d=0.91.

Institution: UCSF, MAPS Public Benefit Corporation
Year: 2021

71.2% of MDMA group no longer met PTSD criteria vs. 47.6% placebo. Effects durable at 6 months.

Institution: UCSF, MAPS PBC, multiple sites
Year: 2023

MDMA binds 5-HT₂B receptors (cardiac valve risk). Clinical evidence that chronic full-dose MDMA associated with VHD. VHD is potential risk with chronic microdosing.

Year: 2023

Repeated MDMA causes dose-dependent decreases in serotonin markers. Recovery requires 6-12+ months. Some individuals show incomplete recovery. Mechanism: Oxidative stress, hyperthermia, autophagy induction.

⚖️ Legal Status

Current legal status in various jurisdictions. Always respect local laws.

Jurisdiction Status Details
USA (Federal)
Schedule I
Emergency scheduling May 31, 1985; Permanent 1988. High abuse potential, no accepted medical use. FDA rejected MDMA-assisted therapy approval (August 2024).
Australia
Schedule 8 (medical) / Schedule 9 (otherwise)
Changed July 1, 2023. FIRST COUNTRY to formally recognize MDMA as medicine (21st century). Schedule 8 for PTSD treatment by authorized psychiatrists; Schedule 9 otherwise.
Czech Republic
Decriminalized (small amounts)
Schedule 4 psychotropic substance. Decriminalized for personal possession since 2010. Up to 4 tablets (~2g MDMA) = administrative misdemeanor, fine up to 15,000 CZK. Over threshold: 2-8 years.
Netherlands
List I ("Hard Drug")
Illegal under Opium Act since 1988. Possession, production, sale prohibited. Gedoogbeleid (tolerance) applies to cannabis only, NOT MDMA. State-funded anonymous pill testing available.
United Kingdom
Class A Drug; Schedule 1
Since 1977 (Misuse of Drugs Act). Possession: up to 7 years; Supply: up to life imprisonment. Research requires Home Office licence.
Canada
Schedule I (CDSA)
Since 1996 (CDSA); moved from Schedule III in 2012. Possession: up to 7 years; Trafficking: up to life. Special Access Program allows therapeutic use; Section 56 exemptions available.
Portugal
Decriminalized
Since 2001 (Law 30/2000). 10-day personal supply (~1g MDMA) threshold. Cases referred to Dissuasion Commissions; most result in no penalty.
Legal information may change. Always verify current legal status in your jurisdiction.

👤 Key Figures

Notable figures associated with the research and history of this substance.

👤

Alexander Shulgin

Chemist, pharmacologist, author

Rediscovered MDMA psychoactive properties (1976). First tested September 1976. Introduced to therapeutic community. Published PiHKAL (1991). Quote: "I feel absolutely clean inside, and there is nothing but pure euphoria."

👤

Ann Shulgin

Lay therapist, author

Co-authored PiHKAL and TiHKAL. Developed Shulgin Rating Scale. Pioneered psychedelic therapy with Jungian perspective. Quote: "He was the scientist, and I was the psychologist."

👤

Leo Zeff

Psychologist, "The Secret Chief", "Johnny Appleseed of MDMA"

Introduced to MDMA by Shulgin (1977). Named it "Adam". Trained ~150 therapists. Facilitated ~4,000 patient sessions. Pioneered MDMA-assisted therapy methodology.

👤

Rick Doblin, Ph.D.

Founder and President of MAPS

Founded MAPS (1986) to make MDMA legal medicine. Ph.D. Public Policy, Harvard. Raised $100+ million for psychedelic research. Led campaign for FDA approval. Quote: "When I learned about MDMA, I realized that this was an extraordinary situation."

👤

Michael Mithoefer, M.D.

Psychiatrist, MAPS Senior Medical Director

Led first FDA/DEA-approved MDMA-PTSD trial (2004). Co-developed MDMA-assisted therapy protocol with wife Annie. Quote: "It feels almost like the inner healer or the MDMA is like a maid doing spring cleaning."

❓ FAQ

**Q: How long until effects begin?**

Oral MDMA typically produces effects within 20-60 minutes, with peak effects at 1.5-2.5 hours.

**Q: How to store MDMA properly?**
Store in a cool, dark, dry place in an airtight container. Crystal form is more stable than in solution. Shelf life in proper conditions: years.

**Q: What are the risks of frequent use?**
Frequent MDMA use causes serotonin depletion, potential neurotoxicity, tolerance ("losing the magic"), depression, cognitive impairment, cardiovascular strain, and possible cardiac valve damage (5-HT₂B activation). **Minimum recommended interval: 3-6 months.**

**Q: Can MDMA be combined with supplements?**
- **5-HTP**: ONLY 24-48 hours AFTER use (NOT before/during - serotonin syndrome risk)
- **Alpha Lipoic Acid**: 300mg before - may reduce neurotoxicity
- **Magnesium**: May reduce jaw clenching
- **Vitamin C**: Antioxidant support

**Q: How to test MDMA purity?**
Use reagent test kits. Marquis reagent turns purple-black with MDMA. DanceSafe sells kits. Lab testing (DrugsData) is more accurate.

**Q: Why is cycling important?**
MDMA depletes serotonin stores with each use. The brain needs 3-6 months to fully replenish serotonin and repair potential neuronal damage.

Ready to Start?

Start tracking your journey

🚀 Start Tracking

Important Legal Notice

⚠️ Personal Responsibility

You use this application entirely at your own risk and responsibility. MicrodosingDiary is only a tool for recording personal experiences.

🚫 Not a Medical Service

This application IS NOT a medical tool, does not provide medical advice, does not diagnose or treat any conditions. Always consult a qualified physician.

⚖️ Legislation and Laws

Many substances used for microdosing are illegal in many countries. Users are fully responsible for complying with local laws. The application does not support or promote illegal activity.

❌ No Guarantees

We provide no guarantees regarding results, safety or efficacy of microdosing. All information is for informational purposes only.

🔞 Age Restriction

Application is intended only for persons over 18 years of age. By using the application you confirm that you are an adult.

🔒 Data Privacy

Your data is private and encrypted. We never share it with third parties without your consent. Application is for personal use only.

By using this application you accept all the above risks and waive any claims against the application operator.